Ticrynafen and probenecid in hyperuricemic, hypertensive men.
In a double-blind crossover study of ticrynafen (TCN) and probenecid (PBC), 9 hypertensive, hyperuricemic men completed 12-wk courses of each drug. With a TCN dose of 125 mg daily, the fall in serum uric acid was prompt, dramatic, and lasting; it was equal to that after PBC, 500 or 1,000 mg daily. There was a small but significant early weight loss (diuresis) after TCN but no antihypertensive effect. Twelve days after resuming TCN for a proposed additional extension study 1 patient suffered acute, reversible bilateral ureteral obstruction, probably caused by sudden urinary uric acid precipitation.
D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004231:Diuresis / Q000187:drug effects; D004311:Double-Blind Method; D006016:Glycolates / Q000009:adverse effects / Q000627:therapeutic use*; D006073:Gout / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010642:Phenoxyacetates / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011339:Probenecid / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*; D014528:Uricosuric Agents / Q000627:therapeutic use*
D006016:Glycolates; D010642:Phenoxyacetates; D010919:Placebos; D013876:Thiophenes; D014528:Uricosuric Agents; D014527:Uric Acid; D003404:Creatinine; D011339:Probenecid